Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (41) 41
life sciences & biomedicine (38) 38
oncology (25) 25
humans (24) 24
melanoma (20) 20
immunotherapy (17) 17
animals (15) 15
cancer (12) 12
tumors (12) 12
mice (10) 10
programmed cell death 1 receptor - antagonists & inhibitors (10) 10
cell biology (9) 9
cell line, tumor (9) 9
melanoma - genetics (9) 9
melanoma - drug therapy (8) 8
neoplasms - immunology (8) 8
antineoplastic agents (7) 7
care and treatment (7) 7
female (7) 7
lymphocytes (7) 7
melanoma - immunology (7) 7
mutation (7) 7
patients (7) 7
antigens (6) 6
immunology (6) 6
metastasis (6) 6
t cells (6) 6
antibodies (5) 5
antineoplastic agents - therapeutic use (5) 5
biochemistry & molecular biology (5) 5
clinical trials (5) 5
combined modality therapy (5) 5
health aspects (5) 5
medical sciences (5) 5
mice, inbred c57bl (5) 5
molecular targeted therapy (5) 5
neoplasms (5) 5
neoplasms - drug therapy (5) 5
neoplasms - therapy (5) 5
research (5) 5
t-lymphocytes - immunology (5) 5
biological and medical sciences (4) 4
cancer therapies (4) 4
cell line (4) 4
gene mutations (4) 4
immune checkpoint (4) 4
interferon-gamma (4) 4
lymphocytes t (4) 4
male (4) 4
mice, scid (4) 4
middle aged (4) 4
pd-1 (4) 4
pd-1 protein (4) 4
programmed cell death 1 receptor (4) 4
programmed cell death 1 receptor - immunology (4) 4
signal transduction (4) 4
tumor (4) 4
usage (4) 4
adoptive cell transfer (3) 3
adult (3) 3
aged (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antineoplastic agents, immunological - pharmacology (3) 3
antineoplastic combined chemotherapy protocols (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
apoptosis (3) 3
biopsy (3) 3
cancer research (3) 3
cancer vaccines (3) 3
cd8-positive t-lymphocytes - immunology (3) 3
checkpoint inhibitor (3) 3
chemotherapy (3) 3
cytotoxicity (3) 3
drug resistance (3) 3
gene expression regulation (3) 3
gene expression regulation, neoplastic (3) 3
genes (3) 3
genetics (3) 3
janus kinase 1 (3) 3
janus kinase 2 (3) 3
major histocompatibility complex (3) 3
medical and health sciences (3) 3
medical prognosis (3) 3
medical research (3) 3
melanoma - metabolism (3) 3
melanoma - therapy (3) 3
monoclonal (3) 3
multidisciplinary sciences (3) 3
neoplasms - metabolism (3) 3
neoplasms - pathology (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
neoplastic (3) 3
pd-l1 (3) 3
pharmacology. drug treatments (3) 3
poster presentation (3) 3
protein kinase inhibitors - therapeutic use (3) 3
science & technology - other topics (3) 3
t-lymphocytes (3) 3
tumor microenvironment (3) 3
xenograft model antitumor assays (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text What does PD-L1 positive or negative mean?
by Ribas, Antoni and Hu-Lieskovan, Siwen
The Journal of experimental medicine, ISSN 0022-1007, 2016, Volume 213, Issue 13, pp. 2835 - 2840
Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Humans | Neoplasm Proteins - immunology | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Animals | Neoplasms - genetics | Neoplasms - immunology | T-Lymphocytes - immunology | Programmed Cell Death 1 Receptor - immunology | T-Lymphocytes - pathology | Neoplasm Proteins - genetics | Neoplasms - pathology | Programmed Cell Death 1 Receptor - genetics | Index Medicus | 314 | Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
by Sharma, Padmanee and Hu-Lieskovan, Siwen and Wargo, Jennifer A and Ribas, Antoni
Cell (Cambridge), ISSN 0092-8674, 02/2017, Volume 168, Issue 4, pp. 707 - 723
T cells | resistance mechanisms | immunotherapy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Neoplasms - therapy | Animals | Neoplasms - immunology | Humans | Immunotherapy | T-Lymphocytes - immunology | Drug Therapy, Combination | Molecular Targeted Therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
by Zaretsky, Jesse M and Garcia-Diaz, Angel and Shin, Daniel S and Escuin-Ordinas, Helena and Hugo, Willy and Hu-Lieskovan, Siwen and Torrejon, Davis Y and Abril-Rodriguez, Gabriel and Sandoval, Salemiz and Barthly, Lucas and Saco, Justin and Homet Moreno, Blanca and Mezzadra, Riccardo and Chmielowski, Bartosz and Ruchalski, Kathleen and Shintaku, I. Peter and Sanchez, Phillip J and Puig-Saus, Cristina and Cherry, Grace and Seja, Elizabeth and Kong, Xiangju and Pang, Jia and Berent-Maoz, Beata and Comin-Anduix, Begoña and Graeber, Thomas G and Tumeh, Paul C and Schumacher, Ton N.M and Lo, Roger S and Ribas, Antoni
The New England journal of medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 9, pp. 819 - 829
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Interferon-gamma - therapeutic use | Humans | Gene Expression Regulation, Neoplastic | Janus Kinase 2 - genetics | Programmed Cell Death 1 Receptor - metabolism | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Sequence Analysis, DNA | Melanoma - secondary | Exome | Drug Resistance, Neoplasm - genetics | Biopsy | Melanoma - genetics | Immunotherapy | Janus Kinase 1 - genetics | Melanoma - drug therapy | Genes, MHC Class I | Mutation | beta 2-Microglobulin - genetics | Usage | Gene mutations | Melanoma | Research | Patients | Health aspects | Antigen presentation | Antigens | PD-1 protein | Metastasis | Gene deletion | Metastases | Pembrolizumab | Major histocompatibility complex | Clonal deletion | Janus kinase 2 | Janus kinase | Clonal selection | Cancer | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Mechanisms of Resistance to PD-1 Checkpoint Blockade
by Moser, Justin C and Hu-Lieskovan, Siwen
Drugs (New York, N.Y.), ISSN 0012-6667, 02/2020, Volume 80, Issue 5, pp. 459 - 465
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Melanoma - immunology | Humans | Melanoma - drug therapy | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Programmed Cell Death 1 Receptor - immunology | Antineoplastic Agents, Immunological - pharmacology | Drug Resistance, Neoplasm - drug effects | Antigens | Immunoglobulins | Dendritic cells | Medical treatment | Melanoma | Clinical trials | Cytotoxicity | Lymphocytes T | Metastasis | Cancer therapies | Patients | Immune checkpoint | Lymphocytes | Cell death | PD-L1 protein | Monoclonal antibodies | Epigenetics | Mutation | Chemokines | Apoptosis | Immune system | Tumors
Journal Article
Details down arrow
5. Full Text Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
by Garcia-Diaz, Angel and Shin, Daniel Sanghoon and Moreno, Blanca Homet and Saco, Justin and Escuin-Ordinas, Helena and Rodriguez, Gabriel Abril and Zaretsky, Jesse M and Sun, Lu and Hugo, Willy and Wang, Xiaoyan and Parisi, Giulia and Saus, Cristina Puig and Torrejon, Davis Y and Graeber, Thomas G and Comin-Anduix, Begonya and Hu-Lieskovan, Siwen and Damoiseaux, Robert and Lo, Roger S and Ribas, Antoni
Cell reports (Cambridge), ISSN 2211-1247, 05/2017, Volume 19, Issue 6, pp. 1189 - 1201
IRF1 | immunotherapy | PD-L1 | PD-L2 | melanoma | interferon receptor signaling pathways | JAK-STATs | PD-1 | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Melanoma - metabolism | Promoter Regions, Genetic | Up-Regulation | Signal Transduction | Programmed Cell Death 1 Ligand 2 Protein - genetics | Humans | Transcriptional Activation | Gene Expression Regulation, Neoplastic | STAT Transcription Factors - metabolism | Programmed Cell Death 1 Ligand 2 Protein - metabolism | Interferon-gamma - metabolism | B7-H1 Antigen - genetics | Interferon Regulatory Factor-1 - genetics | Janus Kinase 1 - metabolism | B7-H1 Antigen - metabolism | Interferon-beta - metabolism | Melanoma - genetics | Janus Kinase 2 - metabolism | Cell Line, Tumor | Protein Binding | Interferon Regulatory Factor-1 - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?
by Pal, Sumanta and Hu-Lieskovan, Siwen and Agarwal, Neeraj
The lancet oncology, ISSN 1470-2045, 11/2019, Volume 20, Issue 11, pp. 1473 - 1474
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
by Hu-Lieskovan, Siwen and Ribas, Antoni
The cancer journal (Sudbury, Mass.), ISSN 1528-9117, 01/2017, Volume 23, Issue 1, pp. 10 - 22
immune-modulatory agent | cancer vaccines | Adoptive cell transfer | oncolytic virus | radiotherapy | combination immunotherapy | epigenetic modification | tumor microenvironment | chemotherapy | checkpoint inhibitor | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Tumor Microenvironment | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Combined Modality Therapy | CTLA-4 Antigen - immunology | B7-H1 Antigen - immunology | Oncolytic Virotherapy | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Neoplasms - therapy | Animals | B7-H1 Antigen - antagonists & inhibitors | Neoplasms - immunology | Neoplasms - radiotherapy | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights